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• Current prescribing practice in paediatric care is based on the empirical
derivation of the dose from a combination of clinical experience and adult
data.
• Optimum drug dosing regimens may be obtained from PK data derived
from measured drug levels. 
• Paediatric PK studies are not conducted due to the relatively large (5-10ml)
volumes of blood required.
• This situation arises from the restriction on blood volume sampled,
particularly for neonates, where an acceptable level is ~50ml.
• DBS sampling system used as a means for collecting small volume blood
samples on sampling card from paediatric patients.
• Quantitative DBS analysis has gained considerable interest in recent years
as it offers many advantages including simplicity of sample collection, storage
and sample transport.
• Paediatric clinical data from DBS for the above drugs is reported.
• Liquid-chromatography mass spectrometry with selected ion monitoring
(LC-MS(SIM)) methods were developed and validated to determine capto-
pril and dexamethasone in dried blood spots (DBS).
• This was investigated as a means of measuring target drug levels from
neonatal patients to explore the possibility of producing paediatric pharmaco-
kinetic (PK) and bioequivalence data to ensure optimum drug dosing regi-
mens.
• Drug stability in the method was also investigated.
Analyte extraction from dried blood spots (DBS)
• Blood spot samples were collected on sampling cards. The cards were pre-
treated with a stabiliser, 1,4 dithiothreitol (DTT), for captopril. 
• The target drugs were solvent extracted from disks punched from the DBS
and analysed (Fig. 1).
Figure 1. Dried blood spot solvent extraction
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MS Conditions
• Mass detectors used with electrospray interface and in positive ion mode.
Captopril:
• Agilent 1100 LC/MSD Ion Trap mass spectrometer
• LC ion trap (IT) MS with Single Ion Monitoring (SIM) at m/z 218.0
Dexamethasone:
• Agilent 1100 LC/1200  mass spectrometer
• LC-MS with Single Ion Monitoring (SIM) at m/z 393.1
METHODS
LC Conditions
Captopril Dexamethasone
Column Zorbax Ecplise C8 150x3mm Zorbax EclipsePlus C18 150x2.1mm
Column temperature 35˚C 23˚C
Flow rate 0.5 ml/min 0.2 ml/min
Mobile Phase A 0.1% Formic Acid in water 0.13% Formic Acid in water
Mobile Phase B 0.1% Formic Acid in ACN ACN
Gradient conditions 60:40 to 0:100 in 3.5 min 60:40 to 20:80 in 6.0 min
Injection volume 25 ml 25 ml 
• The following tests were carried out for the target drugs:
• Optimisation of extraction solvent
• Determination of maximum DBS extraction efficiency
• Instrumental calibration versus extracted drug
• Determination of LoD and LoQ
• Sample stability studies in DBS
Extraction efficiency (recovery)
• Captopril was 90 ± 10% (with DTT in extraction solvent).
• Dexamethasone was 98 ± 6%.
Sample stability
• Captopril: 91 ± 7% recovery after 12 weeks storage at 23˚C.
• Dexamethasone:  Stable in DBS for 7 days at 23˚C and 28 days at 4˚C.
Validation
• Showed good accuracy, precision and good linearity.
• Minimum limits of quantification (LoQ S/N = 10) for captopril and dexam-
ethasone spiked blood standards were as follows:
Captopril Dexamethasone
Range 10-400ng/ml 15-800ng/ml
LoQ 50ng/ml 15ng/ml
R2 0.990 0.985
Selectivity
• No interferences were found at the same retention time as dexametha-
sone (Fig. 2a).
• The captopril DBS LC-MS method exhibited small interference from sam-
pling card (Fig. 2b).
(a) (b)
Figure 2 (a). Overlay EICS for dexamethasone at m/z 393.1 of a blank DBS and DBS spiked with
dexamethasone. 2(b). Overlay EICS for captopril at m/z 218.0 of a blank DBS and DBS spiked with
captopril.
CONCLUSIONS
• NIHR NEAT grant FSE008
• Heel prick DBS sample taken from neonate patient 1 hour post adminis-
tration of 1mg/kg captopril orally.
• Captopril levels calculated to be:
88ng/ml in whole blood or 1.8ng in DBS or 7mg/kg body weight.
• Pilot DBS and plasma comparison studies based on a single 25mg oral
dose of captopril, in one of three paediatric formulations, were carried out
using adult volunteers to assess bioequivalence of formulations (Fig. 3).
(a) (b)
• A PK profile was generated from DBS samples obtained from a neonate
patient administered a 10 day tapering dose of dexamethasone.
• This was compared to the predicted PK profile for dexamethasone in pre-
term neonates (Fig. 4).
Figure 3. A DBS and plasma comparison of PK plots obtained from adult volunteers administered
25mg captopril as (a) an aqueous solution formulation and (b) a suspension formulation
Figure 4. A DBS  PK profile obtained from a neonate patient administered a 10 day tapered dose of
dexamethasone and a comparison with the predicted PK profile.
• The close correlation between the DBS and plasma derived PK plots
demonstrates the validity of the DBS technique.
• The use of small volume blood samples makes the simple DBS approach
particularly appropriate for use in paediatric PK studies, therapeutic drug
monitoring and for assessing bioequivalence of formulations.
• DBS sampling could be used for biomarkers and clinical trials.
Dexamethasone dosing schedule
1. 250mg/kg twice for 3 days
2. 100mg/kg twice for 3 days
3. 50mg/kg twice for 2 days
4. 25mg/kg twice for 2 days
